Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$7.4MCash on Hand
11mo Cash Runway
Follow PBM by emailGet an email when PBM reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about PBM, unsubscribe in one click. Privacy
📄 Latest SEC Filings in Plain English
Oct 21, 2026 ·
Financing Completed a US$2,599,896 investment in PsyLabs at US$2,564 per share (1,014 shares) after two milestones were met: an ibogaine regulatory readiness pack and a cGMP manufacturing agreement with Benuvia by subsidiary TIRC. Ownership of PsyLabs rises to about 43.37%. Form 6-K · SEC filing · Press release
Oct 5, 2026 ·
Deal Subsidiary TIRC entered a manufacturing services agreement with Benuvia Operations, LLC of Round Rock, Texas, for planned U.S. manufacture of pharmaceutical-grade ibogaine API under cGMP. A definitive agreement with PsyLabs, a significant shareholder, is to be concluded on or before November 30, 2026. Form 6-K · SEC filing · Press release
Sep 28, 2026 ·
Deal Subsidiary TIRC signed a binding term sheet with related party PsyLabs for exclusive U.S. ibogaine license, supply and distribution rights. Milestone payments total up to approximately US$1.3 million for the first candidate. Definitive agreement due by November 30, 2026, or the term sheet lapses. Form 6-K · SEC filing · Press release
Sep 23, 2026 ·
Deal Psyence BioMed agreed to invest up to US$5 million in related party PsyLabs, with US$2.4 million committed at US$2,564 per share, plus a share-for-share exchange valued at about US$9 million on each side. It also set up Texas Ibogaine Research Corporation to evaluate a potential ibogaine trial. Form 6-K · SEC filing · Press release
Sep 14, 2026 ·
Deal Psyence BioMed formed Texas Ibogaine Research Corporation to coordinate U.S. ibogaine development, subject to completing definitive licensing arrangements with PsyLabs. Jody Aufrichtig will also serve as CEO of TIRC. Form 6-K · SEC filing · Press release
Aug 26, 2026 ·
Financing Psyence Biomedical registered up to 1,148,598 common shares for resale by two holders. PsyLabs holds 1,146,159 shares issued under a February 2026 put option agreement, and OTBC holds 2,439 shares issued for past services. The company will not receive proceeds from any sales. Form F-3 · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Mar 2027 · Phase 2 · Recruiting · Psilocybin-Assisted Psychotherapy in Cancer Patients With Adjustment Disorder Registry primary completion date, not a results date
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
PBM holds $7.4M in cash and short-term investments and burns about $2M/quarter from operations,
an estimated runway of 11 months at that rate (BioRadar estimate, not company guidance).
Share count 2,293,277 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full PBM picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for PBM and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.